• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    D

    Diabetes Technology Society

    EST. 2001
    54论文总数
    615引用总数

    .

    论文量&引用量时间轴

    机构学者

    论文(54)

    年份
    起
    –
    止
    排序
    1Modifiable Factors Affecting the Postprandial Glycemic Response
    Yue Wu,Tracey McLaughlin, Sayra Gorgani,Agatha F Scheideman, Mandy M Shao, Brady David Hislop, Khoa Hoang,Dalia Perelman, Curtis McGinity, Majid Rodgar,Heyjun Park, Tao Wang,

    The postprandial glycemic response (PPGR) is associated with diabetes and cardiovascular disease and is highly individualized. The PPGR is affected by both physiological and behavioral factors. Attention to the PPGR has dramatically increased recently with the widespread use of continuous glucose monitors. It is expected that individualized control of PPGRs will be important in the prevention of diabetes and its associated complications. In this article, we discuss six modifiable factors associated with the PPGRs, including (1) the glucoregulatory hormones, (2) gastric emptying, (3) salivary or pancreatic amylase, (4) diet, (5) physical exercise, and (6) sleep and circadian rhythm. Modifying these factors may allow for personalized intervention strategies to control the PPGR—to reduce the risk for cardiovascular disease in individuals with varying degrees of glycemia.

    2026Journal of diabetes science and technology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2Research Code Sharing in Support of Gold Standard Science
    David C Klonoff,Juan Espinoza, Julia K Mader, Lutz Heinemann, Claudio Cobelli, David Kerr, Boris Kovatchev, Bijan Najafi, Priya Prahalad, Yaguang Zheng, Mandy M Shao, Agatha F Scheideman,

    Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH's Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article's cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH's GSS principles.

    2026Journal of diabetes science and technology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Integrating Trust into Artificial Intelligence for Medicine: Using Diabetes As the Exemplar Disease
    Mandy M. Shao, Agatha F. Scheideman,David Kerr, Tien Y. Wong,Juan Espinoza,Shahid N. Shah,Mohammed E. Al-Sofiani, Ashley N. Beecy, Dieter Bruno, Elizabeth Healey,Nestoras Mathioudakis,Bin Sheng,

    Artificial Intelligence (AI) has the potential to impact healthcare across multiple domains. In diabetes, a complex chronic disease affecting 600 million people globally, AI is already being used from primary care to tertiary specialist care to reduce patient and clinician burden. However, for medical AI to be widely implemented and applied specifically to diabetes, such stakeholders as patients, clinicians, healthcare administrators, regulators, and AI developers will need to establish trust in this technology. Building trust is a balancing act depending on individual priorities of stakeholders which may not necessarily align. Both probabilistic outputs and “top-choice only” outputs are used in medical AI. To achieve trust in AI for diabetes care, it will be necessary to move beyond expecting only single, deterministic outputs and to establish clear standards for medical AI provenance and performance. This article presents priorities for each of the various stakeholders if they are to develop trust in medical AI and their responsibilities for contributing to the establishment of trust in medical AI. For a medical AI system to be trustworthy, six key attributes must be incorporated including accuracy, reproducibility, privacy/security, transparency, human oversight, and fairness. We present practical methods to achieve each of these six attributes of trustworthy medical AI prioritizing diabetes that are important for all stakeholders.

    2026Journal of Translational Medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Integrating the Glycemia Risk Index into Clinical Practice and Research: A Consensus Report
    Guillermo E Umpierrez,Viral N Shah, Veronica Brady,Mark A Clements,Juan Espinoza, Elizabeth Healey,Michael A Kohn,David M Maahs, Ralph Oiknine, Jane J Seley, Steven P Weitzman,David Kerr,

    A panel of experts in the use of continuous glucose monitoring (CGM) data in the treatment of diabetes met in Burlingame, California on October 27, 2025 to discuss the utility of the glycemia risk index (GRI) for clinical care research and population health management. The GRI composite metric is a single number (on a 0-100 percentile scale-lower is better) based on an expert-determined weighting of the seven individual components in the existing ambulatory glucose profile (AGP). The GRI describes the quality of glycemia based on glucose values collected in a 14-day CGM tracing, thus providing additional insights into CGM profiles beyond the AGP. During the meeting, the mathematical derivation of the GRI metric was presented along with its use for adult and pediatric individuals with diabetes and cancer who require medications that can adversely affect the glucose concentration. Examples where the GRI provided useful insights into the quality of CGM tracings were also discussed by the expert panel. In addition, a new smartphone application, the GRI Calculator, was presented. This app calculates the GRI of a CGM tracing and provides visualization of sequential CGM tracings for a specific individual. The GRI provides a reference measurement for the accuracy of artificial intelligence (AI) models assigning levels of glycemic quality to CGM tracings intended to match the assessments of clinicians. The GRI is now part of the data visualization panel for the Integration of Connected Diabetes Device Data into the Electronic Health Record (iCoDE-2) project, which standardizes both CGM and insulin dosing data. Further exploration of the potential value of the GRI for non-insulin users needs to be undertaken. The panel unanimously recommended that CGM manufacturers and developers of data visualization software for CGMs add the GRI to their data platforms for insulin users.

    2026Journal of diabetes science and technology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5The Need for Clear Medical Data Ownership Laws
    David C. Klonoff, Agatha F. Scheideman, Mandy M. Shao, Cindy N. Ho, Alessandra T. Ayers,Johan Jendle, Henry G. Wykowski, Lutz Heinemann

    Current regulatory frameworks in the United States (US) and the European Union (EU) provide medical data privacy protections, but do not explicitly establish ownership rights. Legislation increasingly recognizes the rights of persons with chronic diseases for data ownership, but clinicians, researchers, public health professionals, and medical device manufacturers can also stake claims to ownership. Effective translational medical research requires policies for using patient-generated data to help society while still protecting the rights of patients from whom the data was obtained. Four increasingly important areas related to the ownership of patient-generated research data are discussed in this article, including (1) US and European laws relating to medical data ownership, (2) stakeholders claiming ownership of medical data, (3) the need for ownership laws to support translational medicine research, and (4) emerging controversies in medical data ownership. Translational research requires secure and legal acquisition of data streams. Technological and policy strategies for data ownership are increasingly needed that respect the rights of all involved stakeholders. No specific legislation in the US and various EU Member States explicitly recognizes ownership rights of medical data. Recent regulatory initiatives like the Trusted Exchange Framework and Common Agreement (TEFCA) in the US and the European Health Data Space Regulation (EHDS) in European Union Member States have strengthened patients’ access to and control of their medical data, but they do not establish medical data ownership rights. The absence of clear ownership rules continues to raise ethical, technical, and legal challenges as medical data sharing expands across international borders.

    2026Journal of Translational Medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 54 篇论文

    合作机构(88)

    Sansum Diabetes Research Institute合作论文 17
    斯坦福大学合作论文 9
    加州大学合作论文 8
    弗吉尼亚大学合作论文 5
    加州大学旧金山分校合作论文 4
    约翰斯·霍普金斯大学合作论文 4
    加利福尼亚大学圣地亚哥分校合作论文 4
    格拉茨医科大学合作论文 4
    Sutter Health合作论文 4
    波士顿儿童医院合作论文 4

    机构统计